Amarin Corporation Investor Relations Material

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular health. The company's primary product is an omega-3-based prescription therapy designed to reduce cardiovascular risk in patients with elevated triglyceride levels. Amarin's research and development efforts center on addressing unmet needs in cardiovascular care through innovative lipid management treatments. The company operates globally, with a focus on expanding its product offerings and advancing cardiovascular treatment options. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.